Form 4: Neurocrine Biosciences Executive Eric Benevich Executes Stock Options and Sells Shares
SEC Form 4 Filing
Chief Commercial Officer Eric Benevich of Neurocrine Biosciences exercised stock options and sold shares on March 14, 2024, according to a Form 4 filing with the SEC.
Summary
- Eric Benevich, Chief Commercial Officer of Neurocrine Biosciences, executed non-qualified stock options and sold shares of common stock on March 14, 2024.
- He exercised options to acquire 5,479 shares at $79.02 and 69,521 shares at $81.05.
- Benevich then sold 5,479 shares and 69,521 shares at a weighted average price of $139.3789.
- These transactions were executed under a pre-arranged Rule 10b5-1 trading plan adopted on November 29, 2023.
- Following these transactions, Benevich directly owns 40,778 shares of common stock and holds options for 46,468 shares.
Sentiment
Score: 5
Explanation: The sentiment is neutral as the document simply reports transactions. The use of a 10b5-1 plan suggests the transactions were pre-planned and not necessarily indicative of a change in sentiment.
Industry Context
Form 4 filings are standard disclosures required by the SEC when corporate insiders, like officers and directors, trade their company's stock. These filings are closely watched by investors for insights into management's perspective on the company's value and future prospects. The use of a 10b5-1 trading plan suggests the transactions were pre-planned and not based on any specific non-public information.
Comparison to Industry Standards
- Comparing Benevich's transactions to those of executives at similar biotech companies like Biogen, Amgen, or Vertex Pharmaceuticals would provide context.
- Analyzing the frequency and size of insider transactions across these companies could reveal whether Benevich's activity is typical or unusual.
- Examining the use of 10b5-1 plans among executives in the biotech industry would also be relevant.
Stakeholder Impact
- Shareholders may interpret these transactions as a signal, although the use of a 10b5-1 plan mitigates concerns about opportunistic trading.
- The transactions have no direct impact on employees, customers, suppliers, or creditors.
Key Dates
| Date | Description |
|---|---|
| 02/07/2019 | Date of grant for non-qualified stock option that vested in 48 equal monthly installments beginning March 7, 2019, expiring February 7, 2029. |
| 01/31/2022 | Date of grant for non-qualified stock option that vested in 48 equal monthly installments beginning February 28, 2022, expiring January 31, 2032. |
| 11/29/2023 | Date Eric Benevich adopted a Rule 10b5-1 trading plan. |
| 02/29/2024 | Date of purchase of 162 shares from the Neurocrine Biosciences, Inc. 2018 Employee Stock Purchase Plan. |
| 03/14/2024 | Date of the reported transactions: exercising stock options and selling shares. |
| 03/15/2024 | Date of the signature on the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.